Technical Analysis for IRWD - Ironwood Pharmaceuticals, Inc.

Grade Last Price % Change Price Change
F 8.51 -5.65% -0.51
IRWD closed down 5.65 percent on Monday, March 18, 2024, on 1.22 times normal volume. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.
2 Watchers
Watchlist Portfolio

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Very Strong Down Down Down

Date Alert Name Type % Chg
Wide Bands Range Expansion 0.00%
Oversold Stochastic Weakness 0.00%
Slingshot Bearish Bearish Swing Setup -5.65%
Pocket Pivot Bullish Swing Setup -5.65%
Volume Surge Other -5.65%
Narrow Range Bar Range Contraction -5.65%
Wide Bands Range Expansion -5.65%
Oversold Stochastic Weakness -5.65%
Bullish Engulfing Bullish -5.13%
Outside Day Range Expansion -5.13%

   Recent Intraday Alerts

Alert Time
Down 5% about 15 hours ago
Down 3% about 16 hours ago
60 Minute Opening Range Breakdown about 18 hours ago
Down 2 % about 18 hours ago
10 DMA Support about 19 hours ago

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Ironwood Pharmaceuticals, Inc. Description

Ironwood Pharmaceuticals, Inc., an entrepreneurial pharmaceutical company, discovers, develops, and commercializes human therapeutic products. The company's lead product candidate, linaclotide, a guanylate cyclase type-C agonist for irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation (CIC) gastrointestinal disorders under the LINZESS name in the United States and Constella name in the European Union. It also has a pipeline focused on the research and development of early development candidates and discovery research programs in various therapeutic areas, including gastrointestinal diseases, central nervous system disorders, allergic conditions, and cardiovascular diseases. Ironwood Pharmaceuticals has collaboration and license agreements with Forest Laboratories, Inc. to develop and commercialize linaclotide in North America; Almirall, S.A to develop and commercialize linaclotide for the treatment of IBS-C, CIC, and other gastrointestinal conditions; Astellas Pharma Inc. to develop and commercialize linaclotide for the treatment of IBS-C, CIC, and other gastrointestinal conditions in Japan, South Korea, Taiwan, Thailand, the Philippines, and Indonesia; and AstraZeneca AB to co-develop and co-commercialize linaclotide in China, including Hong Kong and Macau. The company was formerly known as Microbia, Inc. and changed its name to Ironwood Pharmaceuticals, Inc. in April 2008. Ironwood Pharmaceuticals, Inc. was founded in 1998 and is headquartered in Cambridge, Massachusetts.


Classification

Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Keywords: Gastrointestinal Cardiovascular Disease Therapeutic Products Vascular Disease Central Nervous System Disorders Nervous System Disorders Gastroenterology Peptides Macau Constipation Irritable Bowel Syndrome Digestive Diseases Gastrointestinal Disease Laxatives Chronic Idiopathic Constipation Gastrointestinal Disorders Human Therapeutic Products Linaclotide

Is IRWD a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 15.7
52 Week Low 8.075
Average Volume 5,048,945
200-Day Moving Average 10.71
50-Day Moving Average 12.67
20-Day Moving Average 11.09
10-Day Moving Average 8.87
Average True Range 0.64
RSI (14) 25.37
ADX 50.54
+DI 13.18
-DI 44.99
Chandelier Exit (Long, 3 ATRs) 13.73
Chandelier Exit (Short, 3 ATRs) 10.41
Upper Bollinger Bands 16.90
Lower Bollinger Band 5.27
Percent B (%b) 0.28
BandWidth 104.85
MACD Line -1.39
MACD Signal Line -1.21
MACD Histogram -0.1804
Fundamentals Value
Market Cap 1.33 Billion
Num Shares 156 Million
EPS -6.18
Price-to-Earnings (P/E) Ratio -1.38
Price-to-Sales 5.53
Price-to-Book 2.59
PEG Ratio -0.26
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 9.47
Resistance 3 (R3) 9.57 9.35 9.31
Resistance 2 (R2) 9.35 9.10 9.30 9.25
Resistance 1 (R1) 8.93 8.95 8.82 8.83 9.20
Pivot Point 8.71 8.71 8.66 8.66 8.71
Support 1 (S1) 8.29 8.47 8.18 8.19 7.82
Support 2 (S2) 8.07 8.32 8.02 7.77
Support 3 (S3) 7.65 8.07 7.71
Support 4 (S4) 7.55